11. New therapies and clinical trials

P119: A novel approach to the therapy of Alzheimer’s disease based on peptide-nanoliposome inhibitors of Aβ and tau aggregation
David Allsop, PhD1,2, Mark Taylor, PhD1,2, Nigel Fullwood, PhD1, Maria Michael1, Anthony Aggidis1, Shoona Vincent, PhD2, Mark Dale, MD2
(1). Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK (2). Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

P120: Alzheimer’s disease drug development pipeline: 2017
Jeffrey Cummings1, Garam Lee1, Travis Mortsdorf2, Aaron Ritter1, Kate Zhong3
(1)Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA (2) Touro University Nevada, Henderson, NV, USA (3) Global Alzheimer Platform, Washington, D.C., USA

P121: The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI
Carine Federspiel, MD1,2, Elisabeth Bourkel, PhD1, Jean-Paul Steinmetz, PhD1, 2
(1)Centre for memory and mobility, Luxembourg (2) ZithaSenior, Research&Development, Luxembourg

P122: Pre-clinical and first clinical data of an orally available amyloid beta oligomer eliminating compound that enhances cognition and impedes neurodegeneration in various Alzheimer’s disease mouse models
Dieter Willbold1,2, Janine Kutzsche2, Manfred Windisch3, Dagmar Jürgens2
(1) Institut für Physikalische Biologie, Heinrich-Heine-Universität, Düsseldorf, Germany (2) Institute of Complex Systems, ICS-6: Structural Biochemistry, Research Centre Jülich, Jülich, Germany (3) Neuroscios, Graz, Austria

P123: Cognitive Rehabilitation: A Catalyst to Enhance the Long-Term Treatment in Mild Alzheimer’s disease
Swati Bajpai, PhD Scholar1, Manjari Tripathi, Professor2, RM Pandey, Professor3 A.B Dey, Professor4 & Ashima Nehra Additional Professor1
(1) Department of Clinical Neuropsychology, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India (2) Department of Neurology, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India (3) Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India (4) Department of Geriatric Medicine All India Institute of Medical Sciences, New Delhi, India

P124 Informed Consent Ensuring Access to Anonymized Patient-Level Data and Biospecimen is Critical to Accelerating Innovative Alzheimer Disease Treatments
Stephen P. Arnerić, PhD1, Penny A. Dacks, PhD2, Ann Marie Hake, MD3, James Hendrix, PhD4, Monica Moreno5, Lisa A. Gold, PhD6, Dagmar Theis, PhD6, Mark F. Gordon, M.D.7, Volker D. Kern, PhD1, George Vradenburg8
(1) Critical Path Institute, Tucson, AZ, USA (2) American Epilepsy Society, Chicago, IL, USA (3) Eli Lilly and Company, Indianapolis, IN, USA (4) Alzheimer’s Association, Chicago, IL, USA (5) Merck, West Point, PA, USA (6) Boehringer-Ingelheim, Vienna, Austria (7) Advisor, CT, USA (8) USA Against Alzheimer’s, Washington, DC, USA
P125: Novel strategies against Alzheimer’s Disease using induced human neuronal progenitors and neuronal cells
Ying Lei, PhD1, Gang Li, MD, PhD1, Ying Chen, PhD2, Ge Gao, MD, PhD2 and Jian Zhao, PhD1
(1) GMP Center of Stem Cell Engineering, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China (2) IxCell Biotechnology Co., Ltd, Shanghai, China

P126: A social security network to prevent senior’s cognitive decline and frailty in southern France
Michel Noguès, PhD1, Valérie Bruguière, MA1, Justine Millot-Keurinck, MSc1, Jacques Touchon, MD, PhD2
(1) Caisse Assurance Retraite et Santé Au Travail (Carsat) Languedoc-Roussillon, Montpellier, France (2) Centre Hospitalier Universitaire (CHU), Montpellier, France

P127: P38α kinase inhibition appears to lead to reduction in amyloid-beta generation in patients with Early Alzheimer’s disease
Philip Scheltens MD PhD1, Niels Prins MD PhD1, Adriaan Lammertsma PhD2, Maqsood Yaqub PhD2, Hui-May Chu PhD3, Bart van Berckel MD PhD2, John Alam MD4
(1) Department of Neurology and Alzheimers Center, VU University Medical Center; and the Alzheimers Research Center (ARC), Amsterdam, NL (2) Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NL (3) Anoixis Corporation, Natick, MA, USA (4) EIP Pharma LLC, Cambridge, MA, USA

P128: A novel gamma-secretase modulator for the treatment of Alzheimer Disease
Bengt Winblad1, Johan Lundkvist2, Helena Karlström1, Magnus Halldin2, Johan Sandin2, Gunnar Nordvall2
(1) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden (2) AlzeCure Pharma AB, Huddinge, Sweden

P129: Demonstration of blood-brain-barrier (BBB) penetration and brain target engagement for neflamapimod (p38α kinase inhibitor) in patients with early Alzheimer’s disease (AD)
John Alam1, Charlotte Teunissen2
(1) EIP Pharma LLC, Cambridge, MA, USA (2) Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL

P130: ACD855, development of a positive modulator of neurotrophin signaling for the treatment of Alzheimer’s Disease
Pontus Forsell, PhD1,2, PhD, Gunnar Nordvall1,2, PhD, Johan Lundkvist1,2, PhD, Magnus Halldin1,2, PhD, Märta Dahlström1,3, M.Sc. and Maria Eriksdotter1,4, MD, Prof, and Johan Sandin1,2, PhD 1. AlzeCure Foundation, Karolinska Institutet Science Park, Huddinge, Sweden 2. AlzeCure Pharma AB, Huddinge, Sweden 3. Dept of Neurobiology, Care Sciences and Society, Karolinska Institutet, Sweden 4. Dept Geriatric Medicine, Karolinska university hospital, Huddinge, Sweden

P131: Pharmacokinetics and Delivery to the Brain in Rats of P8, a Peptide Drug Candidate for the Treatment of Alzheimer’s Disease
Nazneen N. Dewji1,2, S. Jonathan Singer1,2, Leah Hanson4, William Frey4, Bruce Morimoto5, David Johnson6, Daniel Dolan6, Marc R. Azar7
(1) Cenna Biosciences Inc., La Jolla, CA, USA (2) Department of Medicine, UC San Diego, La Jolla, CA, USA (3) Division of Biological Sciences, UC San Diego, La Jolla, CA, USA (4) Health Partners Institute, St. Paul, MN, USA (5) Celerion Inc., USA (6) MicroConstants, San Diego, CA, USA(7) Behavioral Pharma, La Jolla, CA, USA
P132: The ABCA-1 agonist CS6253 that reverses apoE4-driven Alzheimer’s disease brain phenotype and cognition decline lowers plasma Neurofilament-light concentrations.

Jan O Johansson1, Anat Boehm-Cagan2, Henrik Zetterberg3,4,5,6, Kaj Blennow3,4, John K. Bielicki7, Daniel M. Michaelson7
1 Artery Therapeutics, Inc., San Ramon, CA; 2Tel Aviv University, Tel Aviv, Israel; 3 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute, London, UK; 7UC Berkeley, Berkley, CA

P133: Novel modulators of molecular chaperone network for the treatment of Alzheimer Disease
Pavel Pavlov PhD, Bengt Winblad MD, PhD, Rajnish Kumar PhD
Karolinska Institutet, Dept of Neuroscience and Society, Div of Neurogeriatrics, Huddinge, Sweden

P134: Cerebral Energy Deficit in Mild to Moderate Alzheimer’s Disease: Strategies to Increase Brain Fuel Supply
Christian-Alexandre Castellano, PhD1, Etienne Croteau, PhD1,2, Melanie Fortier, MSc1, Christian Bocti, MD1,2, Tamas Fulop, MD1,3, Guy Lacombe, MD1,3, Nancy Paquet, MD4, Isabelle Dionne, PhD1,5 and Stephen Cunnane, PhD1,3.
(1) Research Center on Aging, CIUSSSE – CHUS, Sherbrooke, QC, Canada (2) Pharmacology-Physiology department, FMSS, University of Sherbrooke, QC, Canada (3) Medicine department, FMSS, University of Sherbrooke, QC, Canada (4) Nuclear medicine department, FMSS, University of Sherbrooke, QC, Canada (5) Faculty of physical education and sports, University of Sherbrooke, QC, Canada

P135: Pharmacokinetic and target engagement (TE) analysis of BIIB076 in cynomolgus monkeys
Weiping Chen, Julie Czerkowicz, Qin Wang, Danielle Graham
Biogen Inc. Cambridge, MA, USA